DE2951671C2 - Arzneimittelzubereitung mit Antithrombosewirkung und Hemmwirkung auf die Agglomeration der Blutplättchen - Google Patents
Arzneimittelzubereitung mit Antithrombosewirkung und Hemmwirkung auf die Agglomeration der BlutplättchenInfo
- Publication number
- DE2951671C2 DE2951671C2 DE2951671A DE2951671A DE2951671C2 DE 2951671 C2 DE2951671 C2 DE 2951671C2 DE 2951671 A DE2951671 A DE 2951671A DE 2951671 A DE2951671 A DE 2951671A DE 2951671 C2 DE2951671 C2 DE 2951671C2
- Authority
- DE
- Germany
- Prior art keywords
- group
- agglomeration
- sulfinpyrazone
- effect
- blood platelets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000001772 blood platelet Anatomy 0.000 title claims description 21
- 238000005054 agglomeration Methods 0.000 title claims description 14
- 230000002776 aggregation Effects 0.000 title claims description 14
- 230000002401 inhibitory effect Effects 0.000 title claims description 9
- 230000002785 anti-thrombosis Effects 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 claims description 24
- 229960003329 sulfinpyrazone Drugs 0.000 claims description 23
- 150000003222 pyridines Chemical class 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- DNTVKOMHCDKATN-UHFFFAOYSA-N pyrazolidine-3,5-dione Chemical compound O=C1CC(=O)NN1 DNTVKOMHCDKATN-UHFFFAOYSA-N 0.000 claims 2
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 15
- 229960002961 ticlopidine hydrochloride Drugs 0.000 description 15
- MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 description 15
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000002008 hemorrhagic effect Effects 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002110 toxicologic effect Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000697578 Homo sapiens Statherin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 102100028026 Statherin Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7850359A GB2038625B (en) | 1978-12-29 | 1978-12-29 | Therapeutic composition having an antithrombotic and antiblood-platelet-aggregating activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2951671A1 DE2951671A1 (de) | 1980-07-17 |
| DE2951671C2 true DE2951671C2 (de) | 1986-02-20 |
Family
ID=10502010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2951671A Expired DE2951671C2 (de) | 1978-12-29 | 1979-12-21 | Arzneimittelzubereitung mit Antithrombosewirkung und Hemmwirkung auf die Agglomeration der Blutplättchen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4537894A (en, 2012) |
| JP (1) | JPS5592317A (en, 2012) |
| BE (1) | BE880884A (en, 2012) |
| DE (1) | DE2951671C2 (en, 2012) |
| FR (1) | FR2445143A1 (en, 2012) |
| GB (1) | GB2038625B (en, 2012) |
| IE (1) | IE48884B1 (en, 2012) |
| IL (1) | IL58817A (en, 2012) |
| IT (1) | IT1162498B (en, 2012) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749692A (en) * | 1977-06-22 | 1988-06-07 | Sanofi, S.A. | Therapeutic compositions having anti-thrombotic and anti-blood-platelet-aggregating activity |
| US4602014A (en) * | 1984-07-09 | 1986-07-22 | Ciba-Geigy Corporation | Ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives as benzodiazepine receptor modulators |
| JPH01126782U (en, 2012) * | 1988-02-24 | 1989-08-30 | ||
| EP0377413B1 (en) * | 1989-01-04 | 1993-03-31 | ISTITUTO BIOCHIMICO NAZIONALE SAVIO S.r.l. | Pharmaceutical compositions having topical use comprising ticlopidine |
| US5041430A (en) * | 1989-09-18 | 1991-08-20 | Du Pont Mereck Pharmaceutical Company | Oral anticoagulant/platelet inhibitor low dose formulation |
| CH683673A5 (de) * | 1991-10-01 | 1994-04-29 | Otsuka Pharma Co Ltd | Antithromboseharz, Antithromboseröhrchen, Antithrombosefilm und Antithromboseüberzug. |
| ES2311498T3 (es) * | 2000-12-25 | 2009-02-16 | Daiichi Sankyo Company, Limited | Composiciones medicinales que contienen aspirina. |
| CN103374005B (zh) * | 2012-04-11 | 2016-12-14 | 南京信诺泰医药有限公司 | 取代呋喃并哌啶衍生物的合成新方法 |
| CN103360408A (zh) * | 2012-04-11 | 2013-10-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 新的噻吩并吡啶类化合物及其医药用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2215948B1 (en, 2012) * | 1973-02-01 | 1976-05-14 | Centre Etd Ind Pharma | |
| FR2345150A2 (fr) * | 1975-08-06 | 1977-10-21 | Centre Etd Ind Pharma | Nouveaux derives de la thienopyridine, et leur application |
| FR2307538A1 (fr) * | 1975-04-18 | 1976-11-12 | Centre Etd Ind Pharma | Nouveau medicament anti-agregant plaquettaire |
| FR2315274A1 (fr) * | 1975-06-27 | 1977-01-21 | Parcor | Nouveaux derives de la thieno (2,3-c) pyridine, leur preparation et leurs applications |
-
1978
- 1978-12-29 GB GB7850359A patent/GB2038625B/en not_active Expired
-
1979
- 1979-11-22 FR FR7928800A patent/FR2445143A1/fr active Granted
- 1979-11-27 IL IL58817A patent/IL58817A/xx unknown
- 1979-11-28 IE IE2281/79A patent/IE48884B1/en not_active IP Right Cessation
- 1979-12-21 DE DE2951671A patent/DE2951671C2/de not_active Expired
- 1979-12-27 BE BE0/198763A patent/BE880884A/fr not_active IP Right Cessation
- 1979-12-28 IT IT51224/79A patent/IT1162498B/it active
- 1979-12-29 JP JP17401779A patent/JPS5592317A/ja active Granted
-
1983
- 1983-05-16 US US06/494,133 patent/US4537894A/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| NICHTS-ERMITTELT |
Also Published As
| Publication number | Publication date |
|---|---|
| BE880884A (fr) | 1980-06-27 |
| JPS6150926B2 (en, 2012) | 1986-11-06 |
| FR2445143B1 (en, 2012) | 1981-09-11 |
| DE2951671A1 (de) | 1980-07-17 |
| IE48884B1 (en) | 1985-06-12 |
| IE792281L (en) | 1980-06-29 |
| IL58817A0 (en) | 1980-02-29 |
| IT7951224A0 (it) | 1979-12-28 |
| FR2445143A1 (fr) | 1980-07-25 |
| IT1162498B (it) | 1987-04-01 |
| GB2038625A (en) | 1980-07-30 |
| US4537894A (en) | 1985-08-27 |
| GB2038625B (en) | 1983-01-12 |
| JPS5592317A (en) | 1980-07-12 |
| IL58817A (en) | 1982-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0351885B1 (de) | Verwendung von Pentoxifyllin zur Behandlung entzündlicher Erkrankungen | |
| DE68914292T2 (de) | Zusammensetzung zur Behandlung von ischämischen Störungen in Organen. | |
| DE3051205C2 (de) | Pharmazeutische Zubereitung mit antihypartensiver Wirkung, enthaltend eine Chinolonverbindung | |
| DE69329381T2 (de) | Anti-ischaemisches arzneimittel | |
| DE2951671C2 (de) | Arzneimittelzubereitung mit Antithrombosewirkung und Hemmwirkung auf die Agglomeration der Blutplättchen | |
| DE3511609C2 (en, 2012) | ||
| DE69321585T2 (de) | PArENTERALE LÖSUNGEN ENTHALTEND 3-DIALKYLAMINOETHOXYBENZOYLBENZOFURANE | |
| DE69226487T2 (de) | Verwendung von Furanonderivaten zur Vorbeugung oder Behandlung von Autoimmunkrankheiten | |
| DE2403122C2 (en, 2012) | ||
| DE3311922C2 (de) | Verwendung von substituierten 1,4-Benzochinonen bei der Prophylaxe oder Behandlung von Fibrose | |
| DE69115745T2 (de) | Verwendung von Steroidderivaten zur Behandlung der Endometriose | |
| DE2625012B2 (de) | Arzneimittel zur Kontrolle von Leberkrankheiten | |
| DE2451360C2 (de) | 9-Hydroxyellipticin, Verfahren zu dessen Herstellung und seine Verwendung als Arzneimittel | |
| CH642542A5 (de) | Arzneimittel, enthaltend eine kombination aus einem prolinderivat und einem diuretikum. | |
| DE69117879T2 (de) | Arzneimittel für die Verhütung und Behandlung von Krankheiten der Kreislauforgane enthaltend Spiro-3-heteroazolidin-Verbindungen | |
| DE1900772C3 (de) | Salz aus N,N-Dimethylbiguanid und p-Chlorphenoxyessigsäure sowie dieses enthaltende Arzneimittel | |
| CH661208A5 (de) | Arzneimittelpraeparat mit antiarrhythmischer wirkung. | |
| DE2951669C2 (de) | Arzneimittel | |
| DE1667903C3 (de) | Verwendung von Cysteinderivaten zur Herstellung von per oral verabreichbaren Mitteln zur Bekämpfung der Seborrhoe | |
| DE1804448C3 (de) | β-(2-p-Chlorphenyl-thiazol-4-yl)-acrylsäure, pharmazeutisch verträgliche Salze davon und Verfahren zur Herstellung der Verbindung | |
| DE2624918A1 (de) | Arzneimittel mit antiarrhythmischer wirkung | |
| DE3312581A1 (de) | Verwendung von pyrazolonderivaten bei der bekaempfung des wachstums von tumorzellen und der metastasenbildung, arzneimittel hierfuer und verfahren zu deren herstellung | |
| EP1227811A2 (de) | Verwendung von 2-imidazolyl-substituierten carbinolen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen | |
| DE2502679C3 (de) | Phenoxyalkancarbonsäurederivate, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE2752339C3 (de) | Arzneimittel mit Depotwirkung zur Behandlung des Mammakarzinoms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |